Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh (A2RR34) Stock Price & Analysis

A2RR34 Stock Chart & Stats

R$33.36-R$0.42(-1.24%)

At close: Nov 13

Day’s Range: BRL 32.07 - BRL 33.36
52-Week Range: BRL 25.48 - BRL 59.95
Previous Close: BRL 33.78
Volume: N/A
Average Volume (3M): 239
Market Cap: BRL 37.74B
Enterprise Value: BRL 49.36B
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): ―
Beta: -0.17
Next Earnings: Feb 10, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh News

Arrowhead price target lowered to $106 from $120 at Morgan Stanley

Morgan Stanley analyst Michael Ulz lowered the firm’s price target on Arrowhead (ARWR) to $106 from $120 and keeps an Overweight rating on the shares. Published first on TheFly –

1d agoARWR HDP1

Arrowhead price target lowered to $96 from $104 at Stifel

Stifel lowered the firm’s price target on Arrowhead (ARWR) to $96 from $104 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source for

1d agoARWR HDP1

Arrowhead reports FY26 EPS ($5.11) vs ($3.51) last year

Reports FY26 revenue $450.72M, consensus $464.14M. “Arrowhead (ARWR) has fundamentally changed over the past 12 months. Where there was once a company that relied solely on great scientific promise, there

2d agoARWR HDP1

Arrowhead falls -17.7%

Arrowhead (ARWR) is down -17.7%, or -$10.30 to $47.86. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on

5d agoARWR HDP1

Arrowhead falls -15.4%

Arrowhead (ARWR) is down -15.4%, or -$8.96 to $49.20. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on

5d agoARWR HDP1

Arrowhead presents results on two of RNAi based therapies in pipeline at AHA

Arrowhead (ARWR) Pharmaceuticals presented results on two of the RNA interference, RNAi, based therapies in its cardiometabolic pipeline at the American Heart Association, AHA, Scientific Sessions 2026 in Chicago. The

6d agoARWR HDP1

Arrowhead refinances existing credit facility

Arrowhead (ARWR) Pharmaceuticals has completed a refinancing with funds managed by Sixth Street that lowers its borrowing costs, improves near-term liquidity, extends its debt maturity, and increases financial and operational

1w agoARWR HDP1

Arrowhead assumed with a Buy at UBS

UBS analyst Joon Lee assumed coverage of Arrowhead (ARWR) with a Buy rating with a price target of $109, up from $63. The company’s lead drug, Redemplo, reported positive Phase

1M agoARWR HDP1

Arrowhead announces interim results from ongoing Phase 1/2a study of ARO-MAPT

Arrowhead (ARWR) Pharmaceuticals announced interim results from an ongoing Phase 1/2a study of ARO-MAPT, the company’s investigational RNA interference, RNAi, therapeutic being developed as a potential treatment for Alzheimer’s disease

1M agoARWR HDP1

Arrowhead announces US FDA granted plozasiran entry into STAR program

Arrowhead (ARWR) Pharmaceuticals announced that the United States Food and Drug Administration, FDA, has granted plozasiran entry in the Split Real Time Application Review, STAR, pilot program in connection with

1M agoARWR HDP1

Arrowhead: Early ARO-DIMER-PA Data Validate DIMER Platform and Support Buy Rating on Emerging Multi-Target RNAi Potential

J.P. Morgan analyst Brian Cheng has reiterated their bullish stance on ARWR stock, giving a Buy rating on September 9. Brian Cheng has given his Buy rating due to a

1M agoARWR HDP1

Arrowhead: Buy Rating Reiterated as Redemplo Momentum Builds and Pipeline Catalysts Support Unchanged $120 Price Target

Arrowhead Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Ulz from Morgan Stanley reiterated a Buy rating on the stock and has a

3M agoARWR HDP1

Arrowhead: Strong Phase III Plozasiran Data and Priority Review Voucher Drive Accelerated Path to Market and $3B Global Sales Outlook, Supporting Buy Rating

TD Cowen analyst Joseph Thome has maintained their bullish stance on ARWR stock, giving a Buy rating yesterday. Joseph Thome has given his Buy rating due to a combination of

3M agoARWR HDP1

A2RR34 FAQ

What was Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh’s price range in the past 12 months?

Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh lowest stock price was R$25.48 and its highest was R$59.95 in the past 12 months.

What is Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh’s market cap?

Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh’s market cap is R$37.74B.

When is Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh’s earnings last quarter?

Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh released its earnings results on Nov 12, 2026. The company reported -R$0.002 earnings per share for the quarter.

Is Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh pay dividends?

Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh does not currently pay dividends.

What is Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh’s EPS estimate?

Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh have?

Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh has 141,254,470 shares outstanding.

What happened to Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh’s price movement after its last earnings report?

Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh reported an EPS of -R$0.002 in its last earnings report. Following the earnings report the stock price went down -1.243%.

Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh?

Currently, no hedge funds are holding shares in BR:A2RR34

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh (A2RR34) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	6	1	15
Technical Analysis	6	1	3
Moving Averages	0	0	12

Technical Analysis >

Similar Stocks

Stocks similar to BR:A2RR34
Company	Price & Change	Follow
BR:B1AX34Baxter International Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 1/2 Sh
BR:B1MR34Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh
BR:R1DY34Dr Reddy'S Laboratories Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR
BR:R2GE34Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh
BR:T1CH34Bio-Techne Corporation Unsponsored Brazilian Depository Receipt Repr 0.033333333 Sh

Compare BR:A2RR34 Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

A2RR34 Stock Chart & Stats

Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh News

Arrowhead price target lowered to $106 from $120 at Morgan Stanley

Arrowhead price target lowered to $96 from $104 at Stifel

Arrowhead reports FY26 EPS ($5.11) vs ($3.51) last year

Arrowhead falls -17.7%

Arrowhead falls -15.4%

Arrowhead presents results on two of RNAi based therapies in pipeline at AHA

Arrowhead refinances existing credit facility

Arrowhead assumed with a Buy at UBS

Arrowhead announces interim results from ongoing Phase 1/2a study of ARO-MAPT

Arrowhead announces US FDA granted plozasiran entry into STAR program

Arrowhead: Early ARO-DIMER-PA Data Validate DIMER Platform and Support Buy Rating on Emerging Multi-Target RNAi Potential

Arrowhead: Buy Rating Reiterated as Redemplo Momentum Builds and Pipeline Catalysts Support Unchanged $120 Price Target

Arrowhead: Strong Phase III Plozasiran Data and Priority Review Voucher Drive Accelerated Path to Market and $3B Global Sales Outlook, Supporting Buy Rating

A2RR34 FAQ

Arrowhead Pharmaceuticals Inc Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh (A2RR34) Earnings & Revenues

Technical Analysis

Overall Consensus

Similar Stocks

Popular Stocks

Become an Expert with TipRanks Premium